Contact A Lawyer
Have A Potential Case Reviewed By An Attorney
Side effects of the iron deficiency drug Injectafer may result in severely low phosphorous levels, which could result in serious and potentially life-threatening injuries. Injectafer lawsuits are being pursued against the drug makers, for failing to adequately warn users and the medical community.
INJECTAFER LAWSUIT STATUS: Free consultations and case evaluations are being provided by Injectafer lawyers to determine whether financial compensation or settlements may be available for individuals who have developed a condition known as severe hypophosphatemia (HPP).
This Injectafer side effect may result in:
- Cardiac arrest
- Respiratory failure
- Muscle weakness
MANUFACTURER: American Regent, a subsidiary of Daiichi Sankyo.
OVERVIEW: Injectafer (ferric carboxymaltose) is an iron infusion delivered through an intravenous injection for adults with anemia, for whom oral iron supplements can not be used and who have non-dialysis dependent chronic kidney disease.
Originally created by Vifor Pharmaceuticals, the Injectafer injection was approved for use in the United States in 2013 and marketed by Luitpold Pharmaceuticals, which then merged with Daiichi Sankyo subsidiary, American Regent.
While the medication was sold as a safe and effective treatment, increasing evidence suggests that the drug makers knew about serious side effects of Injectafer and withheld information from users, doctors and regulators as part of a scheme to place profits before patient safety.
INJECTAFER SEVERE HPP RISKS: Studies dating back years have suggested potential Injectafer problems may include the potential to dangerously lower blood phosphorous levels. In fact, the original new drug application for Injectafer was rejected by the FDA in 2006, indicating that “clinically important hypophosphatemia” was one of the safety concerns by FDA reviewers.
In 2015, a study published in the International Journal of Rheumatology warned that 13% of patients receiving Injectafer developed severe and prolonged hypophosphatemia.
According to another study published in PLoS One in December 2016, a “high risk” of developing severe and prolonged HPP was linked to use of Ferinject, which is a brand name for the drug sold outside the U.S., containing the same active ingredient as Injectafer.
More recently, a July 2019 study in Alimentary Pharmacology and Therapeutics found high rates of severe and persistent HPP in patients with inflammatory bowel disease given Injectafer.
HPP is a disturbance of the body’s electrolytes caused by low levels of phosphate in the blood. Some research has suggested that FCM increases the production of fibroblast growth factor 23 hormones in the body. Increases of this hormone are known to cause HPP.
FIND OUT IF YOU MAY QUALIFY FOR AN INJECTAFER SETTLEMENT: As a result of the drug makers’ failure to adequately warn about the risks associated with their medication, Injectafer lawyers are evaluating whether users may be entitled to compensation through a product liability lawsuit or class action lawsuit.
According to allegations presented in the claims, Daiichi Sankyo and it’s American Regent ahd Luitpold Pharmaceuticals subsidiaries withheld important safety information about the HPP risks from Injectafer, and provided false and misleading label warnings and information about Injectafer’s safety for years.
To request a free consultation and claim evaluation to determine whether you, a friend or family member may be entitled to financial compensation through a lawsuit, submit information for review to an Injectafer injury lawyer.